FINWIRES · TerminalLIVE
FINWIRES

Wedbush表示，尽管预期有所下调，但艺电交易仍按计划进行。

By

-- Wedbush周三在一份报告中指出，艺电(EA)似乎正按计划完成其待定交易，而在线服务业务的增长、利润率的提升以及《FC》、《麦登橄榄球》和《Apex英雄》等稳定系列游戏的持续表现，将支撑其未来的业绩。 这家投资公司下调了2027财年和2028财年的业绩预测，原因是其目前预计在线服务业务的贡献将更为谨慎，主要来自《战地6》的玩家群体。同时，Wedbush将2027财年的净预订量预期从83.5亿美元下调至80.7亿美元，每股收益预期从9.41美元下调至8.73美元。 对于2028财年，Wedbush将净预订量预期从85.5亿美元下调至82.9亿美元，每股收益预期从9.90美元下调至9.27美元。但该公司补充说，由于新游戏发布相关支出减少以及研发、销售和市场营销方面的杠杆作用增强，其仍然预计2027财年的营业利润率将有所提高。 预计到 2027 财年，在线服务业务将增长约 9%，占总预订量的 76% 左右，这主要得益于《Apex 英雄》、《全球足球》以及其他持续运营的游戏系列。 Wedbush 维持对 Electronic Arts 的“中性”评级和 210 美元的目标价，并表示该目标价已反映了已公布的交易价格。

Price: $201.66, Change: $+0.09, Percent Change: +0.04%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL